MET is a proto-oncogene and its overexpression is associated with disease progression. As per recent studies MET amplification plays a major role for acquired resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Domain Inhibitor (EGFR-TKI). MET amplification has been reported in approximately 5% of patients not treated with EGFR-TKI and up to 20% of patients with acquired resistance to Gefitinib or Erlotinib. Over-expression of MET has been observed in variety of neoplasms of kidney, lung, head & neck, ovary, breast, thyroid, brain, stomach, pancreas and colon. This amplification has been associated with an unfavorable prognosis in Non-Small Cell Lung Cancer (NSCLC) and resistance to EGFR inhibitors.